Article: Epidermal Growth Factor Receptor-mutated Lung Cancer as the Initial Manifestation of Germline TP53 Mutation Associated Cancer

Epidermal growth factor receptor (EGFR) mutation-driven lung cancer is a rare occurrence in patients with Li-Fraumeni syndrome (LFS) characterized by germline mutations in the tumor protein 53 (TP53) gene. Here we describe a case of primary EGFR mutation-driven lung adenocarcinoma in a young woman with LFS. There is only one other reported case with such presentation. We review the interactions between the TP53 gene and EGFR pathways facilitating lung carcinogenesis. We also review other cases with similar presentations described in the literature and the response to tyrosine kinase inhibitors (TKI) in this rare patient population.

Citing Articles

EGFR-mutated lung cancer as a secondary neoplasm in a patient with Li-Fraumeni syndrome: case report.

Cortes Valenzuela D, Vega Medina P, Palma Garcia F, Castillo-Fernandez O AME Case Rep. 2024; 8:76.

PMID: 39091538 PMC: 11292096. DOI: 10.21037/acr-23-206.

Potential genetic modifiers for somatic EGFR mutation in lung cancer: a meta-analysis and literature review.

Cheng Y, Gan Y, Liu D, Davies M, Li W, Field J BMC Cancer. 2019; 19(1):1068.

PMID: 31703574 PMC: 6842246. DOI: 10.1186/s12885-019-6317-6.

References

1.

Hainaut P, Pfeifer G . Somatic TP53 Mutations in the Era of Genome Sequencing. Cold Spring Harb Perspect Med. 2016; 6(11). PMC: 5088513. DOI: 10.1101/cshperspect.a026179. View

2.

Kawaguchi T, Koh Y, Ando M, Ito N, Takeo S, Adachi H . Prospective Analysis of Oncogenic Driver Mutations and Environmental Factors: Japan Molecular Epidemiology for Lung Cancer Study. J Clin Oncol. 2016; 34(19):2247-57. DOI: 10.1200/JCO.2015.64.2322. View

3.

Ricordel C, Labalette-Tiercin M, Lespagnol A, Kerjouan M, Dugast C, Mosser J . EFGR-mutant lung adenocarcinoma and Li-Fraumeni syndrome: report of two cases and review of the literature. Lung Cancer. 2014; 87(1):80-4. DOI: 10.1016/j.lungcan.2014.11.005. View

4.

Bougeard G, Renaux-Petel M, Flaman J, Charbonnier C, Fermey P, Belotti M . Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers. J Clin Oncol. 2015; 33(21):2345-52. DOI: 10.1200/JCO.2014.59.5728. View

5.

Labbe C, Cabanero M, Korpanty G, Tomasini P, Doherty M, Mascaux C . Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Lung Cancer. 2017; 111:23-29. DOI: 10.1016/j.lungcan.2017.06.014. View

6.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E . Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13(3):239-46. DOI: 10.1016/S1470-2045(11)70393-X. View

7.

Jorissen R, Walker F, Pouliot N, Garrett T, Ward C, Burgess A . Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res. 2003; 284(1):31-53. DOI: 10.1016/s0014-4827(02)00098-8. View

8.

Ludes-Meyers J, Subler M, Shivakumar C, Munoz R, Jiang P, Bigger J . Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. Mol Cell Biol. 1996; 16(11):6009-19. PMC: 231603. DOI: 10.1128/MCB.16.11.6009. View

9.

Vaughan C, Pearsall I, Singh S, Windle B, Deb S, Grossman S . Addiction of lung cancer cells to GOF p53 is promoted by up-regulation of epidermal growth factor receptor through multiple contacts with p53 transactivation domain and promoter. Oncotarget. 2016; 7(11):12426-46. PMC: 4914296. DOI: 10.18632/oncotarget.6998. View

10.

Valdez J, Nichols K, Kesserwan C . Li-Fraumeni syndrome: a paradigm for the understanding of hereditary cancer predisposition. Br J Haematol. 2016; 176(4):539-552. DOI: 10.1111/bjh.14461. View

Epidermal Growth Factor Receptor-mutated Lung Cancer As the Initial Manifestation of Germline TP53 Mutation Associated Cancer